journal
MENU ▼
Read by QxMD icon Read
search

Lancet Diabetes & Endocrinology

journal
https://www.readbyqxmd.com/read/29776896/islet-transplantation-in-type-1-diabetes-moving-forward
#1
Shareen Forbes, Peter A Senior, A M James Shapiro
No abstract text is available yet for this article.
May 15, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29776895/islet-transplantation-versus-insulin-therapy-in-patients-with-type-1-diabetes-with-severe-hypoglycaemia-or-poorly-controlled-glycaemia-after-kidney-transplantation-trimeco-a-multicentre-randomised-controlled-trial
#2
Sandrine Lablanche, Marie-Christine Vantyghem, Laurence Kessler, Anne Wojtusciszyn, Sophie Borot, Charles Thivolet, Sophie Girerd, Domenico Bosco, Jean-Luc Bosson, Cyrille Colin, Rachel Tetaz, Sophie Logerot, Julie Kerr-Conte, Eric Renard, Alfred Penfornis, Emmanuel Morelon, Fanny Buron, Kristina Skaare, Gwen Grguric, Coralie Camillo-Brault, Harald Egelhofer, Kanza Benomar, Lionel Badet, Thierry Berney, François Pattou, Pierre-Yves Benhamou
BACKGROUND: Islet transplantation is indicated for patients with type 1 diabetes with severe hypoglycaemia or after kidney transplantation. We did a randomised trial to assess the efficacy and safety of islet transplantation compared with insulin therapy in these patients. METHODS: In this multicentre, open-label, randomised controlled trial, we randomly assigned (1:1) patients with type 1 diabetes at 15 university hospitals to receive immediate islet transplantation or intensive insulin therapy (followed by delayed islet transplantation)...
May 15, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29754897/correction-to-lancet-diabetes-endocrinol-2018-published-online-may-4-http-dx-doi-org-10-1016-s2213-8587-18-30105-0
#3
(no author information available yet)
No abstract text is available yet for this article.
May 10, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29752194/sex-specific-relevance-of-diabetes-to-occlusive-vascular-and-other-mortality-a-collaborative-meta-analysis-of-individual-data-from-980-793-adults-from-68-prospective-studies
#4
(no author information available yet)
BACKGROUND: Several studies have shown that diabetes confers a higher relative risk of vascular mortality among women than among men, but whether this increased relative risk in women exists across age groups and within defined levels of other risk factors is uncertain. We aimed to determine whether differences in established risk factors, such as blood pressure, BMI, smoking, and cholesterol, explain the higher relative risks of vascular mortality among women than among men. METHODS: In our meta-analysis, we obtained individual participant-level data from studies included in the Prospective Studies Collaboration and the Asia Pacific Cohort Studies Collaboration that had obtained baseline information on age, sex, diabetes, total cholesterol, blood pressure, tobacco use, height, and weight...
May 8, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29752193/diabetes-and-cardiovascular-mortality-the-impact-of-sex
#5
Anna Norhammar
No abstract text is available yet for this article.
May 8, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29735394/dorzagliatin-monotherapy-in-chinese-patients-with-type-2-diabetes-a-dose-ranging-randomised-double-blind-placebo-controlled-phase-2-study
#6
Dalong Zhu, Shenglian Gan, Yu Liu, Jianhua Ma, Xiaolin Dong, Weihong Song, Jiao'e Zeng, Guixia Wang, Wenjuan Zhao, Qiu Zhang, Yukun Li, Hui Fang, Xiaofeng Lv, Yongquan Shi, Haoming Tian, Linong Ji, Xin Gao, Lihui Zhang, Yuqian Bao, Minxiang Lei, Ling Li, Longyi Zeng, Xiaoying Li, Xinghua Hou, Yu Zhao, Tianxin Hu, Xiaoyun Ge, Guiyu Zhao, Yongguo Li, Yi Zhang, Li Chen
BACKGROUND: Glucokinase acts as a glucose sensor in the pancreas and a glucose processor in the liver, and has a central role in glucose homoeostasis. Dorzagliatin is a new, dual-acting, allosteric glucokinase activator that targets both pancreatic and hepatic glucokinases. Dorzagliatin has good pharmacokinetic and pharmacodynamic properties in humans, and provides effective 24-h glycaemic control and improves glucose sensitivity in patients with type 2 diabetes. We aimed to assess the efficacy and safety of dorzagliatin monotherapy at different doses in Chinese patients with type 2 diabetes...
May 4, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29735393/new-hope-for-glucokinase-activators-in-type-2-diabetes
#7
André J Scheen
No abstract text is available yet for this article.
May 4, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29699867/precision-medicine-in-the-management-of-type-2-diabetes
#8
REVIEW
Anna L Gloyn, Daniel J Drucker
The study of type 2 diabetes has been driven by advances in human genetics, epigenetics, biomarkers, mechanistic studies, and large clinical trials, enabling new insights into disease susceptibility, pathophysiology, progression, and development of complications. Simultaneously, several new drug classes with different mechanisms of action have been introduced over the past two decades, accompanied by data about cardiovascular safety and non-glycaemic outcomes. In this Review, we critically examine the progress and integration of this new science into clinical practice, and review opportunities for enabling the use of precision medicine in the diagnosis and treatment of type 2 diabetes...
April 23, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29685861/target-blood-pressure-and-kidney-protection
#9
Giuseppe Mancia
No abstract text is available yet for this article.
April 20, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29685860/intensive-systolic-blood-pressure-control-and-incident-chronic-kidney-disease-in-people-with-and-without-diabetes-mellitus-secondary-analyses-of-two-randomised-controlled-trials
#10
Srinivasan Beddhu, Tom Greene, Robert Boucher, William C Cushman, Guo Wei, Gregory Stoddard, Joachim H Ix, Michel Chonchol, Holly Kramer, Alfred K Cheung, Paul L Kimmel, Paul K Whelton, Glenn M Chertow
BACKGROUND: Guidelines, including the 2017 American College of Cardiology and American Heart Association blood pressure guideline, recommend tighter control of systolic blood pressure in people with type 2 diabetes. However, it is unclear whether intensive lowering of systolic blood pressure increases the incidence of chronic kidney disease in this population. We aimed to compare the effects of intensive systolic blood pressure control on incident chronic kidney disease in people with and without type 2 diabetes...
April 20, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29674136/glycaemic-control-and-glycaemic-variability-in-older-people-with-diabetes
#11
Hermes J Florez
No abstract text is available yet for this article.
April 16, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29674135/mean-hba-1c-hba-1c-variability-and-mortality-in-people-with-diabetes-aged-70-years-and-older-a-retrospective-cohort-study
#12
Angus Forbes, Trevor Murrells, Henrietta Mulnier, Alan J Sinclair
BACKGROUND: Glycaemic targets for older people have been revised in recent years because of concern that more stringent targets are associated with increased mortality. We aimed to investigate the association between glycaemic control (mean HbA1c ) and variability (variability of HbA1c over time) and mortality in older people with diabetes. METHODS: We did a 5-year retrospective cohort study using The Health Improvement Network database, which includes data from 587 UK primary care practices...
April 16, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29661701/correction-to-lancet-diabetes-endocrinol-2017-5-680-81
#13
(no author information available yet)
No abstract text is available yet for this article.
April 13, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29661700/correction-to-lancet-diabetes-endocrinol-2018-6-274
#14
(no author information available yet)
No abstract text is available yet for this article.
April 13, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29661699/effect-of-neprilysin-inhibition-on-renal-function-in-patients-with-type-2-diabetes-and-chronic-heart-failure-who-are-receiving-target-doses-of-inhibitors-of-the-renin-angiotensin-system-a-secondary-analysis-of-the-paradigm-hf-trial
#15
Milton Packer, Brian Claggett, Martin P Lefkowitz, John J V McMurray, Jean L Rouleau, Scott D Solomon, Michael R Zile
BACKGROUND: Neprilysin inhibition has favourable effects on experimental diabetic nephropathy. We sought to assess the effects of neprilysin inhibition on the course of renal function in patients with type 2 diabetes. METHODS: In the randomised, double-blind PARADIGM-HF trial, the effects of sacubitril/valsartan (97 mg/103 mg twice daily) were compared with enalapril (10 mg twice daily) in 8399 patients with mild-to-moderate chronic heart failure and systolic dysfunction...
April 13, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29655878/fluid-retention-aldosterone-excess-and-treatment-of-resistant-hypertension
#16
David A Calhoun
No abstract text is available yet for this article.
April 11, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29655877/endocrine-and-haemodynamic-changes-in-resistant-hypertension-and-blood-pressure-responses-to-spironolactone-or-amiloride-the-pathway-2-mechanisms-substudies
#17
Bryan Williams, Thomas M MacDonald, Steve V Morant, David J Webb, Peter Sever, Gordon T McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Sandosh Padmanabhan, Isla S Mackenzie, Jackie Salsbury, Morris J Brown
BACKGROUND: In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. METHODS: PATHWAY-2 was a randomised, double-blind crossover trial done at 14 UK primary and secondary care sites in 314 patients with resistant hypertension. Patients were given 12 weeks of once daily treatment with each of placebo, spironolactone 25-50 mg, bisoprolol 5-10 mg, and doxazosin 4-8 mg and the change in home systolic blood pressure was assessed as the primary outcome...
April 11, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29653811/correction-to-lancet-diabetes-endocrinol-2018-published-online-on-feb-20-http-dx-doi-org-10-1016-s2213-8587-18-30035-4
#18
(no author information available yet)
No abstract text is available yet for this article.
April 10, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29631783/denosumab-a-new-treatment-option-for-glucocorticoid-induced-osteoporosis
#19
Elena Tsourdi, Lorenz C Hofbauer
No abstract text is available yet for this article.
April 6, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29631782/denosumab-versus-risedronate-in-glucocorticoid-induced-osteoporosis-a-multicentre-randomised-double-blind-active-controlled-double-dummy-non-inferiority-study
#20
Kenneth G Saag, Rachel B Wagman, Piet Geusens, Jonathan D Adachi, Osvaldo D Messina, Ronald Emkey, Roland Chapurlat, Andrea Wang, Nicola Pannacciulli, Willem F Lems
BACKGROUND: Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and is associated with an estimated annual fracture rate of 5%. We aimed to assess the efficacy and safety of denosumab compared with risedronate in glucocorticoid-induced osteoporosis. METHODS: We did a 24-month, double-blind, active-controlled, double-dummy, non-inferiority study at 79 centres in Europe, Latin America, Asia, and North America. Eligible patients were aged 18 years or older and were receiving glucocorticoids (≥7·5 mg prednisone daily, or equivalent) for at least 3 months (glucocorticoid continuing) or less than 3 months (glucocorticoid initiating) before screening...
April 6, 2018: Lancet Diabetes & Endocrinology
journal
journal
47944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"